Compare NCMI & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCMI | BWAY |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Advertising | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 450.8M |
| IPO Year | 2006 | N/A |
| Metric | NCMI | BWAY |
|---|---|---|
| Price | $3.45 | $14.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $5.63 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 457.6K | 167.5K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ 52.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.20 | $309.69 |
| Revenue Next Year | $6.22 | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.92 | $7.84 |
| 52 Week High | $6.18 | $26.63 |
| Indicator | NCMI | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 58.17 | 57.82 |
| Support Level | $3.17 | $15.97 |
| Resistance Level | $3.90 | $16.63 |
| Average True Range (ATR) | 0.14 | 0.69 |
| MACD | 0.05 | 0.57 |
| Stochastic Oscillator | 93.81 | 98.52 |
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.